Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04236921 Extension Study in Crohn's Disease
NCT01345318Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2011
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of pacibekitug in Crohn's disease, sponsored by Pfizer. Primary endpoints: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs at Week 48 and Percentage of Participants Developing Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) at Week 76. Started Jun 2011; status: completed.
02
Drugs
pacibekitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01345318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345318.